Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Dizal announces positive pooled data of sunvozertinib in EGFR TKI-resistant NSCLC: Shanghai, China Friday, December 13, 2024, 18:00 Hrs [IST] Dizal, a biopharmaceutical company co ...

The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...

In the conclusion to our interview with Joshua K. Sabari, MD, which focused on the first-line approval of amivantamab (Ami; ...

The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.

Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...

Susan Wojcicki, the late CEO of YouTube, had a message for the world just weeks before she passed away in August: “Lung ...

AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...

The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan (sac-TMT) for advanced NSCLC with EGFR ...

Scientists have identified the following genes associated with carcinogenesis (the development of cancer) in the lungs. Mutations of the EGFR gene can alter the production of a protein called ...

Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen ...